by mzeal | Apr 2, 2019 | Diagnosis & Therapy
Vaccine may restore NSCLC response to checkpoint inhibitors BY CHRISTINE KILGORE MDedge News SAN FRANCISCO – An experimental allogeneic cellular vaccine combined with the checkpoint inhibitor nivolumab (Opdivo) may boost the immune response in patients with previously...
by mzeal | Apr 1, 2019 | Diagnosis & Therapy
Neoadjuvant atezolizumab shrinks NSCLC tumors BY CHRISTINE KILGORE MDedge News SAN FRANCISCO – One-fifth of patients with resectable non–small cell lung cancer had a major pathologic response to neoadjuvant therapy with the immune checkpoint inhibitor atezolizumab...
by mzeal | Apr 1, 2019 | Diagnosis & Therapy
Interview with Roy S. Herbst, MD, PhD, on Immunotherapy in Lung Cancer BY CHRISTINE KILGORE MDedge News Roy S. Herbst, MD, PhD, is the Ensign Professor of Medicine (Medical Oncology) and Professor of Pharmacology at Yale University, and Chief of Medical Oncology at...
by mzeal | Apr 1, 2019 | Biomarkers
Neutrophil-lymphocyte ratio predicts response to immunotherapy in NSCLC BY CHRISTINE KILGORE MDedge News SAN FRANCISCO – For patients with non–small cell lung cancer, the ratio of neutrophils to lymphocytes appears to be predictive of response to immune checkpoint...
by mzeal | Apr 1, 2019 | Biomarkers
Blood tumor mutational burden predicts immunotherapy outcomes in NSCLC BY CHRISTINE KILGORE MDedge News For patients with non–small cell lung cancer (NSCLC), a blood test of tumor mutational burden (TMB) could predict clinical responses to checkpoint inhibitors,...
